[go: up one dir, main page]

CA3033240C - Antagonistes de tlr7/8 et leurs utilisations - Google Patents

Antagonistes de tlr7/8 et leurs utilisations

Info

Publication number
CA3033240C
CA3033240C CA3033240A CA3033240A CA3033240C CA 3033240 C CA3033240 C CA 3033240C CA 3033240 A CA3033240 A CA 3033240A CA 3033240 A CA3033240 A CA 3033240A CA 3033240 C CA3033240 C CA 3033240C
Authority
CA
Canada
Prior art keywords
compound
date
methyl
piperidin
date received
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3033240A
Other languages
English (en)
Other versions
CA3033240A1 (fr
Inventor
Brian A. Sherer
Xiaoling Chen
Esther CLEARY
Nadia Brugger
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority claimed from PCT/US2017/045671 external-priority patent/WO2018031434A1/fr
Publication of CA3033240A1 publication Critical patent/CA3033240A1/fr
Application granted granted Critical
Publication of CA3033240C publication Critical patent/CA3033240C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente divulgation concerne généralement les composés fonctionnant comme antagonistes de récepteurs de type toll 7/8 (TLR7/8) et l'utilisation desdits composés dans le traitement de troubles immunitaires ou tout autre trouble lié à une surexpression de TLR7/8, comme les rhumatismes articulaires, la maladie inflammatoire chronique de l'intestin ou le cancer. Certains modes de réalisation sont dirigés vers un composé de formule I-a ou I-b qui sont des antagonistes doubles de TLR7 et TLR8, ou un sel connexe acceptable sur le plan pharmaceutique, dans lequel le cycle B est et RI est-CH3, -CF3, -CN, -0CH3, ou-OCF3.
CA3033240A 2016-08-08 2017-08-07 Antagonistes de tlr7/8 et leurs utilisations Active CA3033240C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371917P 2016-08-08 2016-08-08
US62/371,917 2016-08-08
PCT/US2017/045671 WO2018031434A1 (fr) 2016-08-08 2017-08-07 Antagonistes de tlr7/8 et leurs utilisations

Publications (2)

Publication Number Publication Date
CA3033240A1 CA3033240A1 (fr) 2018-02-15
CA3033240C true CA3033240C (fr) 2025-10-28

Family

ID=

Similar Documents

Publication Publication Date Title
US11512069B2 (en) TLR7/8 antagonists and uses thereof
AU2021218041B2 (en) Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
US10836750B1 (en) TLR7/8 antagonists and uses thereof
WO2020025517A1 (fr) Antagonistes de tlr7/8 et leurs utilisations
CA3033240C (fr) Antagonistes de tlr7/8 et leurs utilisations
BR112019000696B1 (pt) Antagonistas de tlr7/8, seu uso, composição farmacêutica, e kit